PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
April 23, 2026EJC Skin CancerOpen Access

Therapeutic challenges in oral mucosal melanoma: two clinical cases

View Full Paper
Ask AI
Bookmark
Share

Authors

IRI. Villegas RomeroRRR. Román-CheuqueFRF. Rodríguez-Posadas

Discussion

Loading...

Member takes

Overview

Case presentations highlight challenges and therapeutic responses in oral mucosal melanoma, suggesting a combination of therapies.

Key Points

  • This research aims to present therapeutic strategies in managing oral mucosal melanoma, highlighting challenges in treatment.
  • Presentation of two clinical cases of mucosal melanoma with detailed treatment regimens.
  • Use of immunotherapy agents ipilimumab and nivolumab alongside topical imiquimod.
  • Assessment of treatment responses and disease progression through clinical evaluations and histological examinations.
  • In Case 1, significant response was achieved with immunotherapy despite treatment interruption due to toxicity.
  • In Case 2, initial partial response was observed after the introduction of axitinib and radiotherapy.
  • Both cases underscore the aggressive nature of mucosal melanoma and the complexities of effective treatment.

Cite This Study

Romero et al. (2026) studied this question.

synapsesocial.com/papers/69e9b71b85696592c86eb158https://doi.org/10.1016/j.ejcskn.2026.101072
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Neoadjuvant ipilimumab plus nivolumab therapy as a potential organ preservation strategy in mucosal melanoma: case report2024 · 6 citations
  2. 2A case series on oral mucosal melanoma: Presenting beyond the typical2026
  3. 3Case report: Durable complete response of a mucosal melanoma of the rectum after neoadjuvant immunotherapy with ipilimumab plus nivolumab2024 · 2 citations
  4. 4Phase II trial of First-Line Axitinib Plus Nivolumab in Patients with Advanced Mucosal Melanoma.2026
  5. 5Complete Response to Nivolumab‐Relatlimab Following Progression of Invasive Sinonasal Mucosal Melanoma on First‐Line Nivolumab‐Ipilimumab: A Case Report2026